drugset / Trial / NCT07680946
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Timeline
- Start
- 2026-07-27
- Primary completion
- 2028-12-12
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |